CSL Ltd Annual Report 2020

Strong progress in market demand has been seen over the past twelve months which lays a good foundation to supporting our 2030 strategy. In saying this, predicting the underlying outlook in the market and providing a trend is challenging given the circumstances presented by COVID-19. In the medium term CSL expects to continue to grow through developing differentiated plasma-derived and recombinant products, expanding markets and indications for those products as well as seasonal and pandemic influenza vaccines. We believe that demand for our plasma, recombinant and vaccine products continues to be robust, particularly for immunoglobulins and influenza vaccines. Governments around the world recognise the essential products and capabilities that we provide to their communities. It is unlikely that this demand will change in a material way in the medium term. The COVID-19 pandemic does, however, present a challenge for the global plasma industry. The collection of plasma has been adversely impacted in the past fewmonths as communities respond to shelter-in-place orders, extended lockdowns and other government actions. To mitigate this, we have a number of initiatives in place to sustain plasma collections. It is our view that, at some point, the pandemic will recede and, with that in mind, we continue to invest in plasma collection and manufacturing facilities as well as our hallmark research and development programs. Seqirus is expected to continue to performwell and deliver another strong profitable year. Governments around the world want to protect their populations from the potential co-infection of influenza and COVID-19. This, together with Seqirus’ differentiated products, underpins this expectation. We have faced an exceptionally challenging environment with the COVID-19 pandemic, and although the situation remains highly fluid, we remain positive about CSL’s prospects for the future. Driven by our promise, and guided by our Values in making our decisions, we remain committed to delivering innovative medicines that saves lives, protect public health and help people with life-threatening medical conditions live full lives. More information in relation to our outlook is provided in our full year investor briefing pack, and further information on the factors that could affect our outlook is provided in Our Material Risks. CSL Limited Annual Report 2020 20 6 Outlook